NRC FORM 374
(7-94)

U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE

Amendment No. 19

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

302670

Licensee	
1. Bloomington Hospital	In accordance with letter dated May 8, 1997
2. P.O. Box 1149 Bloomington, IN 47402	3. License Number 13-10408-02 is amended in its entirety to read as follows:
	4. Expiration Date August 31, 2000
	5. Docket or Reference No. 030-01644

6. Byproduct, Source, and/or Special Nuclear Material	7. Chemical and/or Physical Form	8. Maximum Amount that Licensee May Possess at Any One Time Under This License
A. Any byproduct material identified in 10 CFR 35.100	A. Any radiopharmaceutical identified in 10 CFR 35.100	A. As needed
B. Any byproduct material identified in 10 CFR 35.200	B. Any radiopharmaceutical identified in 10 CFR 35.200	B. As needed
C. Any byproduct material identified in 10 CFR 35.300	C. Any radiopharmaceutical identified in 10 CFR 35.300(excluding iodine-131 for thyroid carcinoma)	C. As needed (not to exceed one curie of iodine-131)
D. Any byproduct material identified in 10 CFR 35.400	D. Any brachytherapy source identified in 10 CFR 35.400	D. As needed
E. Any byproduct material identified in 10 CFR 31.11	E. Prepackaged Kits	E. As needed
F. Gadolinium-153	F. Sealed sources (North American Scientific, Inc. Model 3601)	F. 4 sources, not to exceed 300 millicuries each

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
13-10408-02

Docket or Reference Number
030-01644

Amendment No. 19

9. Authorized Use:

A. Medical use described in 10 CFR 35.100.

B. Medical use described in 10 CFR 35.200.

C. Medical use described in 10 CFR 35.300 (excluding iodine-131 for thyroid carcinoma).

D. Medical use described in 10 CFR 35.400.

E. In vitro studies.

F. Two sources to be used in an Adac Laboratories Transmission Line Source Housing VANTAGE device for medical radiography in humans. Two sources in shipping containers for replacement of the sources.

CONDITIONS

10. A. Licensed material shall be used only at the licensee's facilities located at 605-625 West Second Street, Bloomington, Indiana.

B. Licensed material in Item 6.C., limited to strontium-89, may be received and used at the licensee's facilities located at 2620 Coda Drive, Bloomington, Indiana.

11. Radiation Safety Officer: William Van de Riet, Ph.D.

12. Licensed material listed in Item 6 above is only authorized for use by, or under the supervision of, the following individuals for the materials and uses indicated:

Authorized Users	Material and Use
A. Douglas D. Geiger, M.D.	10 CFR 35.100, 35.200, 31.11 and gadolinium-153 for medical radiography.
B. Jonathan T. Stafford, M.D.	10 CFR 35.100, 35.200, 31.11 and gadolinium-153 for medical radiography.
C. Donald C. Buehner, M.D.	10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma), 31.11 and gadolinium-153 for medical radiography.
D. Philip R. Doering, M.D.	10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma), 31.11 and gadolinium-153 for medical radiography.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
13-10408-02

Docket or Reference Number
030-01644

Amendment No. 19

Authorized Users	Material and Use
E. James G. Ferguson, M.D.	10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma), 31.11 and gadolinium-153 for medical radiography.
F. Julie A. Hornback-Widman, M.D.	10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma), 31.11 and gadolinium-153 for medical radiography.
G. Bruce N. Monson, M.D.	10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma), 31.11 and gadolinium-153 for medical radiography.
H. Phillip S. Rudman, M.D.	10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma) and gadolinium-153 for medical radiography.
I. George K. Wolfer Jr., M.D.	10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma), 31.11 and gadolinium-153 for medical radiography.
J. Douglas W. Widman, M.D.	10 CFR 35.300 (excluding iodine-131 for thyroid carcinoma), 35.400 and 31.11.
K. Bharati R. Kharkar, M.D.	10 CFR 35.400, 31.11, phosphorus-32 for treatment of polycythemia vera, leukemia, bone metastases and intracavity treatments, and strontium-89 for palliative treatment of bone metastases.
L. Stephen L. Bellis, M.D.	10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma), 35.400, 31.11 and gadolinium-153 for medical radiography.
M. T. L. Megremis, M.D.	10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma), 35.400, 31.11 and gadolinium-153 for medical radiography.
N. Roger A. Reimers M.D.	10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma), 35.400, 31.11 and gadolinium-153 for medical radiography.
O. Mark A. Bisesi, M.D.	10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma), 31.11, and gadolinium-153 for medical radiography.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
13-10408-02

Docket or Reference Number
030-01644

Amendment No. 19

13. A. Sealed sources shall be tested for leakage and/or contamination at intervals not to exceed 6 months or at such other intervals as specified by the certificate of registration referred to in 10 CFR 32.210.

B. In the absence of a certificate from a transferor indicating that a leak test has been made within 6 months prior to the transfer, a sealed source received from another person shall not be put into use until tested.

C. Sealed sources need not be leak tested if:

(i) they contain only hydrogen-3; or

(ii) they contain only a radioactive gas; or

(iii) the half-life of the isotope is 30 days or less; or

(iv) they contain not more than 100 microcuries of beta and/or gamma emitting material or not more than 10 microcuries of alpha emitting material; or

(v) they are not designed to emit alpha particles, are in storage, and are not being used. However, when they are removed from storage for use or transferred to another person, and have not been tested within the required leak test interval, they shall be tested before use or transfer. No sealed source shall be stored for a period of more than 10 years without being tested for leakage and/or contamination.

D. The leak test shall be capable of detecting the presence of 0.005 microcurie of radioactive material on the test sample. If the test reveals the presence of 0.005 microcurie or more of removable contamination, a report shall be filed with the U.S. Nuclear Regulatory Commission in accordance with 10 CFR 30.50(b)(2), and the source shall be removed immediately from service and decontaminated, repaired, or disposed of in accordance with Commission regulations. The report shall be filed within 5 days of the date the leak test result is known with the U.S. Nuclear Regulatory Commission, Region III, ATTN: Chief, Nuclear Materials Safety Branch, 801 Warrenville Road, Lisle, Illinois 60532-4351. The report shall specify the source involved, the test results, and corrective action taken.

E. Tests for leakage and/or contamination shall be performed by the licensee or by other persons specifically licensed by the Commission or an Agreement State to perform such services.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
13-10408-02

Docket or Reference Number
030-01644

Amendment No. 19

14. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below, except for minor changes in the medical use radiation safety procedures as provided in 10 CFR 35.31. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated April 25, 1990; and

B. Letters dated March 7, 1991, June 30, 1994, September 10, 1996, February 14, 1997, and March 17, 1997; and

C. Letter received July 14, 1994.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date 9 June 1997

By William T. Russell
Materials Licensing Branch, Region III

COPY

BETWEEN:

License Fee Management Branch, ARM
and
Regional Licensing Sections

(FOR LFMS USE)
INFORMATION FROM LTS

Program Code: 02120
Status Code: 0
Fee Category: 7C 2B
Exp. Date: 20000831
Fee Comments:
Decom Fin Assur Reqd: N

S7

LICENSE FEE TRANSMITTAL

A. REGION

1. APPLICATION ATTACHED
   Applicant/Licensee: BLOOMINGTON HOSPITAL
   Received Date: 970519
   Docket No: 3001644
   Control No.: 302670
   License No.: 13-10408-02
   Action Type: Amendment

2. FEE ATTACHED
   Amount: 440
   Check No.: 11745

3. COMMENTS

Signed D. Hersey
Date 5-30-97

B. LICENSE FEE MANAGEMENT BRANCH (Check when milestone 03 is entered /✓/)

1. Fee Category and Amount: 7C 2B $440

2. Correct Fee Paid. / Application may be processed for:
   Amendment ✓
   Renewal
   License

3. OTHER

Signed SE
Date 6/2/97

JUN 05 1997

Log Blank I III
Remitter
Check No. 11745
Amount $440
Fee Category 7C 2B
Type of Fee Amd
Date Check Rec'd 6/2/97
Date Completed
By SE

RGN-2 MAIL RM
'97 JUN -2 AM 11:45

Office of The President P.O. Box 1149 Bloomington, Indiana 47402 812-336-9555

Bloomington Hospital

May 8, 1997

United States Nuclear Regulatory Commission
Region III
801 Warrenville Road
Lisle, IL 60532-4351

Re: USNRC Materials License No. 13-10408-02

Dear Sir/Madam:

Please amend our USNRC Materials License No. 13-10408-02 to include Mark A. Bisesi, M.D. for use of:

> 10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma therapy), 31.11 and for use of the Gadolinium-153 source contained in the Vantage Attenuation Correction System associated with one of our gamma cameras

Dr. Mark A. Bisesi is listed as a user on USNRC Materials License No. 21-15462-01 issued to St. Lawrence Hospital in Lansing, MI (copy enclosed).

Enclosed is a check in the amount of $440.00 to cover the cost of this amendment.

If you have any questions, please feel free to contact William G. Van de Riet, Ph.D. (RSO) at (812) 335-2814.

Sincerely yours,

Nancy S. Carlstedt

Nancy S. Carlstedt
President

Enclosures: Copy of License No. 21-15462-01
Check ($440.00)

302670

JUN 05 1997

RECEIVED
MAY 19 1997
REGION III

An Organization of Local Council of Women

Pm 5-14-97

JUN 05 1997

MAY 19 1997

MATERIALS LICENSE

Amendment No. 18

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	
1. St. Lawrence Hospital Sisters of Mercy	In accordance with the letter dated January 20, 1997 3. License Number 21-15462-01 is amended in its entirety to read as follows:
2. 1210 W. Saginaw Street Lansing, MI 48915	4. Expiration Date February 28, 2004
	5. Docket or Reference No. 030-09151

6. Byproduct, Source, and/or Special Nuclear Material	7. Chemical and/or Physical Form	8. Maximum Amount that Licensee May Possess at Any One Time Under This License
A. Any byproduct material identified in 10 CFR 35.100	A. Any radiopharmaceutical identified in 10 CFR 35.100	A. As needed
B. Any byproduct material identified in 10 CFR 35.200	B. Any radiopharmaceutical identified in 10 CFR 35.200	B. As needed
C. Any byproduct material identified in 10 CFR 35.300	C. Any radiopharmaceutical identified in 10 CFR 35.300 (excluding iodine-131 for thyroid carcinoma therapy)	C. As needed (not to exceed one curie of iodine-131)
D. Any byproduct material identified in 10 CFR 31.11	D. Prepackaged Kits	D. As needed

9. Authorized Use:

A. Medical use described in 10 CFR 35.100.

B. Medical use described in 10 CFR 35.200.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number: 21-15462-01

Docket or Reference Number: 030-09151

Amendment No. 18

9. Authorized Use (Continued)

C. Medical use described in 10 CFR 35.300 (excluding iodine-131 for thyroid carcinoma therapy)

D. In vitro studies.

CONDITIONS

10. Location of Use: 1210 W. Saginaw, Lansing, Michigan

11. Radiation Safety Officer: John Chalmers Crockett, M.D.

12. Licensed material listed in Item 6 above is only authorized for use by, or under the supervision of, the following individuals for the materials and uses indicated:

Authorized Users	Material and Use
Stephen P. Wilensky, M.D.	10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma therapy) and 31.11.
Gerald R. Aben, M.D.	10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma therapy) and 31.11.
John Chalmers Crockett, M.D.	10 CFR 35.100, 35.200 and 31.11.
Gordon L. Bartek, M.D.	10 CFR 35.100, 35.200 and 31.11.
E. Tryciecky, D.O.	10 CFR 35.100, 35.200 and 31.11.
Teresa G. Kelly, M.D.	10 CFR 35.100, 35.200 and 31.11.
Kent W. Graham, D.O.	10 CFR 35.100, 35.200 and 31.11.
Joseph R. Pernicone, D.O.	10 CFR 35.100, 35.200 and 31.11.
Alexander Gottschalk, M.D.	10 CFR 35.100, 35.200 and 31.11.
E. James Potchen, M.D.	10 CFR 35.100, 35.200 and 31.11.

12. (Continued)

Authorized Users	Material and Use
K. P. Gunaga, Ph.D.	10 CFR 31.11.
Michael J. Potchen, M.D.	10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma therapy) and 31.11.
Michael P. Buetow, M.D.	10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma therapy) and 31.11.
Mark A. Bisesi, M.D.	10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma therapy) and 31.11.
Mark C. Delano, M.D.	10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma therapy) and 31.11.
Ruggero Battan, M.D.	10 CFR 35.300 (excluding iodine-131 for thyroid carcinoma therapy).

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below, except for minor changes in the medical use radiation safety procedures as provided in 10 CFR 35.31. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated October 11, 1993; and

B. Letter dated January 20, 1997.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date 2/13/97

By Michael F. Weber
Nuclear Materials Licensing Branch, Region III

HMW

DATE: 5-22-97

CORRESPONDENCE CLARIFICATION SHEET

REVIEWER: ~~BJ HOLT~~ WATSON

LICENSEE: Bloomington Hosp.

LICENSE NUMBER: 13-10408-02

The following correspondence has been received from the above licensee and it is not clear what action(s) is(are) required: Please review this correspondence and indicate which of the following applies, and please return to Debbie Hersey, as soon as possible.

☐ Additional Information to Control No. _____.
Process in as a new action, additional information, and no fee required.

☐ Process as new licensing action. Review has already been started on Control No._____ and this information cannot be combined with current in-house action.

☐ Can be combined with Control No. _____. Review has not started.

☐ Appears to be information for the license file - file it.

☐ Licensee is adding Nuclear Pharmacists.

Amendment is necessary _____. Amendment is not necessary _____.
(Information for license file)

☑ Licensee is adding authorized users.

A check is included ✓. No check is included _____.

Amendment is necessary ✓. Amendment is not necessary _____.
(This is a Notification)

☐ Process in as a new licensing action:

A. Amendment _____
B. Renewal _____
C. New License Application _____

☐ Other: _____

Thank You For Your Help!!! 10/16/96

JUN 1 0 1997

Nancy S. Carlstedt
President
Bloomington Hospital
P.O. Box 1149
Bloomington, IN 47402

Dear Ms. Carlstedt:

Enclosed is Amendment No. 19 to your NRC Material License No. 13-10408-02 in accordance with your request.

Please review the enclosed document carefully and be sure that you understand all conditions. If there are any errors or questions, please notify the U.S. Nuclear Regulatory Commission, Region III office at (630) 829-9887 so that we can provide appropriate corrections and answers.

Please be advised that your license expires at the end of the day, in the month, and year stated in the license. Unless your license has been terminated, you must conduct your program involving byproduct materials in accordance with the conditions of your NRC license, representations made in your license application, and NRC regulations. In particular, note that you must:

1. Operate in accordance with NRC regulations 10 CFR Part 19, "Notices, Instructions and Reports to Workers; Inspections," 10 CFR Part 20, "Standards for Protection Against Radiation," and other applicable regulations.

2. Notify NRC, in writing, within 30 days:

   a. When an authorized user or Radiation Safety Officer permanently discontinues performance of duties under the license or has a name change; or

   b. When the mailing address listed on the license changes. (No fee is required if the location of byproduct material remains the same.)

3. In accordance with 10 CFR 30.36(b) and/or license condition, notify NRC, promptly, in writing, and request termination of the license when you decide to terminate all activities involving materials authorized under the license.

302670

4. Request and obtain a license amendment before you:

   a. Receive or use byproduct material for a clinical procedure permitted under Part 35 but not permitted by your license issued pursuant to this Part;

   b. Permit anyone, except individuals described in 10 CFR 35.13(b), to work as an authorized user under the license;

   c. Change Radiation Safety Officers;

   d. Order byproduct material in excess of the amount, or radionuclide, or form different than authorized on the license;

   e. Add or change the areas of use or address or addresses of use identified in the license application or on the license; or

   f. Change ownership of your organization.

5. Submit a complete renewal application with proper fee or termination request at least 30 days before the expiration date of your license. You will receive a reminder notice approximately 90 days before the expiration date. Possession of byproduct material after your license expires is a violation of NRC regulations. A license will not normally be renewed, except on a case-by-case basis, in instances where licensed material has never been possessed or used.

In addition, please note that NRC Form 313 requires the applicant, by his/her signature, to verify that the applicant understands that all statements contained in the application are true and correct to the best of the applicant's knowledge. The signatory for the application should be the licensee or certifying official rather than a consultant.

You will be periodically inspected by NRC. Failure to conduct your program in accordance with NRC regulations, license conditions, and representations made in your license application and supplemental correspondence with NRC will result in enforcement action against you. This could include issuance of a notice of violation, or imposition of a civil penalty, or an order suspending, modifying or revoking your license as specified in the General Statement of Policy and Procedure for NRC Enforcement Actions. Since serious consequences to employees and the public can result from failure to comply with NRC requirements, prompt and vigorous enforcement action will be taken when

dealing with licensees who do not achieve the necessary meticulous attention to detail and the high standard of compliance which NRC expects of its licensees.

Sincerely,

Original Signed By
W. P. Reichhold
Nuclear Materials Licensing Branch

License No.: 13-10408-02
Docket No.: 030-01644

Enclosure: Amendment No. 19

DOCUMENT NAME: M:\03001644.CL7
To receive a copy of this document, indicate in the box: "C" = Copy without attachment/enclosure "E" = Copy with attachment/enclosure "N" = No copy

OFFICE	DNMS/RIII							
NAME	WREICHHOLD:jaw							
DATE	06/ /97							

OFFICIAL RECORD COPY

UNITED STATES
NUCLEAR REGULATORY COMMISSION
REGION III
801 WARRENVILLE ROAD
LISLE, ILLINOIS 60532-4351

May 30, 1997

William Van DeRiet, Ph.D.
Radiation Safety Officer
Bloomington Hospital
P. O. Box 1149
Bloomington, IN 47402

SUBJECT: ACKNOWLEDGEMENT OF CORRESPONDENCE
(Letter Dated 05/08/97)

Dear Licensee:

In response to your request, we have completed the initial processing, which is an administrative review of your application for a(n):

___ New License X Amendment ___ Renewal
___ Termination ___ Auth User (Amendment not required)
___ Other_____

No administrative deficiencies were identified during this initial review. However, it should be noted that a technical review may identify omissions in the submitted information.

It appears that your request is routine (see 1-3 below, as applicable).

1. New and amendment actions are normally processed within 90 days, unless we find major deficiencies, or policy issues requiring central program office assistance.

2. Renewal actions are normally processed within 180 days, however, under timely filing (before expiration), you may continue to operate under your existing license.

3. Termination actions are normally processed within 90 days, unless confirmatory surveys following decontamination/decommissioning activities are involved.

A copy of your correspondence has been forwarded to our Licensing Fee and Debt Collection Branch (301/415-6097) for approval of the fee category and amount, if required.

If you have a compelling safety or business-related reason for requesting expedited review, please contact the Materials Licensing Branch at (630) 829-9887. We will try to complete your request as soon as practicable. Any correspondence about this request should reference the control number.

Nuclear Materials Support Branch

Mail Control No. 302670
License No. 13-10408-02